CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCyte's Glycoprotein Products in Heart Attack Disease Model
BOTHELL, Washington (euro adhoc) -
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
cooperations/pharmaceuticals
CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG) has selected the Cardiovascular Phenotyping Core at Washington University School of Medicine in St. Louis to perform a study to further evaluate CellCyte's glycoprotein products. The goal of the study is to investigate the efficiency of CellCyte's glycoprotein products in a preclinical model of myocardial infarction (heart attack).
"We look forward to working with the scientific team at Washington University on this study, which will continue to advance the research and development efforts for our glycoprotein products," noted Ronald W. Berninger, Ph.D., Chief Scientific Officer at CellCyte. "These are highly experienced researchers, as demonstrated by the fact that they perform more than 6,000 surgical and imaging studies annually. Outsourcing a portion of the preclinical work allows us to move our program forward more quickly and is complementary to our in-house scientific efforts," Berninger added.
About the Washington University School of Medicine
Washington University School of Medicine's 2,100 employed and volunteer
faculty physicians also are the medical staff of Barnes-Jewish and St. Louis
Children's Hospitals. The School of Medicine is one of the leading medical
research, teaching, and patient care institutions in the nation, currently
ranked third in the nation by U.S. News & World Report. Through its affiliations
with Barnes-Jewish and St. Louis Children's Hospitals, the School of Medicine is
linked to BJC HealthCare.About CellCyte Genetics
CellCyte Genetics is a biotechnology company engaged in the discovery,
development and commercialization of stem cell enabling therapeutic products.
CellCyte is developing products to allow more efficient delivery and increased
retention of adult stem cells to diseased organs, such as the heart. The goal of
these therapies is to increase the number of stem cells delivered to a damaged
organ, thereby markedly increasing organ healing and functional restoration. The
Company's lead product in development, CCG-TH30, is designed to send autologous
bone marrow-derived (adult) stem cells to the heart of patients after a heart
attack.CellCyte Genetics | 1725 220th Street SE | Bothell | Washington | 98021 | USA
For further information see: http://www.cellcyte.com.
Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS
DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED,
AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE
FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS,
EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL
INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN
FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES
THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS,
PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS
THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY,
FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE,"
"PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS
AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS
ASSOCIATED WITH THE RESEARCH AND DEVELOPMENT OF CCG-TH30. OTHER RISKS INCLUDE
RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE PRODUCTS AND
COMPANIES AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND
DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT
EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.
THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE,
AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS,
OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN
THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS,
PLANS, EXPECTATIONS, AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE
REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS, OR
INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE
INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED
IN THE COMPANY'S PERIODIC REPORTS FILED FROM TIME TO TIME WITH THE UNITED STATES
SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE COMPANY'S MOST RECENT REPORTS
ON FORM 10-KSB AND FORM 10-Q. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT
OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD,
THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS
NEWS RELEASE.SOURCE CellCyte Genetics Corporation
Web site: http:/www.cellcyte.com
end of announcement euro adhoc
Further inquiry note:
North America, Investor Relations of CellCyte Genetics Corporation,
+1-877-688-5050, Investorrelations@cellcyte.com
Branche: Biotechnology
ISIN: US15116P1030
WKN: A0MLCV
Börsen: Börse Frankfurt / Open Market
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse München / free trade